What is the appropriate HbA1c target for adults with type 2 diabetes?

Goal A1c for Type 2 Diabetes

For most adults with type 2 diabetes, target an HbA1c between 7% and 8%, with the specific goal determined by individual patient factors including diabetes duration, comorbidities, hypoglycemia risk, and life expectancy. 1

Standard Target: HbA1c <7% for Most Patients

• The baseline recommendation is HbA1c <7% (53 mmol/mol) for many nonpregnant adults with type 2 diabetes, supported by Grade A evidence from randomized controlled trials demonstrating reduced microvascular complications. 1
• This target balances long-term prevention of retinopathy, nephropathy, and neuropathy against treatment burden and adverse effects. 1

More Stringent Target: HbA1c <6.5% for Select Patients

Consider targeting HbA1c <6.5% (48 mmol/mol) ONLY in patients who meet ALL of the following criteria: 1

• Short duration of diabetes (newly diagnosed or early disease)
• Treated with lifestyle modifications alone OR metformin monotherapy (not on medications associated with hypoglycemia)
• Long life expectancy (>15 years)
• No significant cardiovascular disease
• No history of severe hypoglycemia

The NICE guideline specifically recommends 6.5% for patients managed by lifestyle and diet alone or with a single non-hypoglycemia-causing drug. 1

Critical caveat: The AACE/ACE recommendation of ≤6.5% carries only Grade D evidence (lowest quality), and this aggressive target lacks demonstrated clinical benefit below 6.5%. 1 The ACCORD trial targeting <6.5% was stopped early due to increased mortality. 1

Less Stringent Target: HbA1c 7-8% for High-Risk Patients

Target HbA1c between 7% and 8% (or even <8%) for patients with ANY of the following: 1

• History of severe hypoglycemia requiring assistance
• Limited life expectancy (<10 years)
• Advanced microvascular complications (end-stage renal disease, proliferative retinopathy)
• Advanced macrovascular complications (prior MI, stroke, heart failure)
• Extensive comorbid conditions (dementia, cancer, severe COPD, liver failure)
• Long-standing diabetes where intensive control has been difficult despite multiple agents
• High cardiovascular disease risk or established CVD
• Cognitive impairment
• Polypharmacy concerns
• Older age (≥80 years) or nursing home residence

The ICSI guideline emphasizes that efforts to achieve HbA1c <7% may increase risk for death, weight gain, and hypoglycemia in these populations. 1

Deintensification When HbA1c <6.5%

If a patient achieves HbA1c <6.5% on pharmacologic therapy, deintensify treatment by reducing medication doses, eliminating agents (if on multiple drugs), or discontinuing pharmacologic therapy entirely. 1

• No trials demonstrate clinical benefit from targeting HbA1c below 6.5%, and the ACCORD and ADVANCE trials showed increased harms at these levels. 1
• Exception: Metformin may be continued given its low hypoglycemia risk, tolerability, and cardiovascular benefits, though even this adds medication burden with minimal benefit at very low HbA1c levels. 1

Avoid HbA1c Targets in End-of-Life Populations

Do not set specific HbA1c targets for patients with life expectancy <10 years due to advanced age (≥80 years) or terminal conditions; instead, focus on symptom management (avoiding polyuria, polydipsia, polyphagia, and hyperglycemic complications). 1

• The harms of intensive glycemic control outweigh benefits in these populations, as microvascular benefits require 10-15 years to manifest. 1

Recent Evidence on Optimal Targets

A 2021 meta-analysis of 15 randomized controlled trials found that HbA1c in the 7.1-7.7% range was associated with significant reductions in retinopathy (46%), macroalbuminuria (52%), non-fatal stroke (36%), and all-cause mortality (22%), challenging more aggressive targets. 2

• In patients with diabetes duration ≥10 years, reducing HbA1c to ≤7.0% was offset by increased all-cause mortality (21%) and non-fatal MI (17%). 2
• This suggests the optimal range may be higher than traditionally recommended, particularly in established disease. 2

A 2023 analysis of the ACCORD study demonstrated that HbA1c variability should guide target selection: patients with low variability benefit from lower targets, those with medium variability achieve optimal outcomes around 7.5%, and those with high variability have lowest mortality risk around 7.8%. 3

Common Pitfalls to Avoid

• Do not pursue HbA1c <6.5% in patients on insulin or sulfonylureas due to severe hypoglycemia risk without proven benefit. 1
• Do not maintain intensive targets in patients who develop severe hypoglycemia—immediately liberalize goals to 7-8%. 1
• Do not ignore quality of life—if efforts to achieve target impair daily functioning, relax the goal. 1
• Remember that FPG control alone is insufficient—post-prandial glucose must be addressed to achieve HbA1c <7%, particularly in insulin-deficient phenotypes. 4